Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.

Mital Patel; Michael A Vogelbaum; Gene H Barnett; Rakesh Jalali; Manmeet S Ahluwalia

doi:10.1517/13543784.2012.703177

Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.

Mital Patel, Michael A Vogelbaum, Gene H Barnett, Rakesh Jalali, Manmeet S Ahluwalia

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Expert Opinion on Investigational Drugs
Volume	21
DOIs	https://doi.org/10.1517/13543784.2012.703177
State	Published - Aug 14 2012

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences
Oncology

Access to Document

10.1517/13543784.2012.703177License: Unspecified

Cite this

@article{c27d3c86b1fa4246990f30e9f91d9bdd,

title = "Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.",

author = "Mital Patel and Vogelbaum, {Michael A} and Barnett, {Gene H} and Rakesh Jalali and Ahluwalia, {Manmeet S}",

note = "The complex genetic origin of GBM makes it challenging to identify molecular subsets that may benefit from specific targeted therapies. Pathway inhibition, via multisite kinase inhibitors or a carefully selected combination of molecular drugs with or without cytotoxic agents, is currently undergoing ...",

year = "2012",

month = aug,

day = "14",

doi = "10.1517/13543784.2012.703177",

language = "American English",

volume = "21",

journal = "Expert Opinion on Investigational Drugs",

}

TY - JOUR

T1 - Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.

AU - Patel, Mital

AU - Vogelbaum, Michael A

AU - Barnett, Gene H

AU - Jalali, Rakesh

AU - Ahluwalia, Manmeet S

N1 - The complex genetic origin of GBM makes it challenging to identify molecular subsets that may benefit from specific targeted therapies. Pathway inhibition, via multisite kinase inhibitors or a carefully selected combination of molecular drugs with or without cytotoxic agents, is currently undergoing ...

PY - 2012/8/14

Y1 - 2012/8/14

UR - https://www.ncbi.nlm.nih.gov/pubmed/22731981

U2 - 10.1517/13543784.2012.703177

DO - 10.1517/13543784.2012.703177

M3 - Article

VL - 21

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

ER -

Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.

Disciplines

Access to Document

Other files and links

Cite this